Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.

Authors

Yousef Zakharia

University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA

Yousef Zakharia , Rohan Garje , James A. Brown , Kenneth Gerard Nepple , Laila Dahmoush , Katherine Gibson-Corley , Douglas Spitz , Mohammed M. Milhem , Youcef M. Rustum

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.

First Author: Rohan Garje

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.

First Author: Renee Maria Saliby

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.

First Author: Omar Alhalabi

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

First Author: Matthew Scott Ernst